UniQure unwraps Phase 1/2 gene therapy data for Huntington’s disease

UniQure said Wednesday that a high dose of its experimental gene therapy AMT-130 for Huntington’s disease hit the primary endpoint in a Phase 1/2 trial, and it’s now targeting an FDA submission early next year ...